362 related articles for article (PubMed ID: 19891693)
1. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD
Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693
[TBL] [Abstract][Full Text] [Related]
2. Expression and significance of PTEN in canine mammary gland tumours.
Qiu C; Lin D; Wang J; Wang L
Res Vet Sci; 2008 Oct; 85(2):383-8. PubMed ID: 18082231
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the local expression of the relaxin system in canine mammary tumours.
Lamp O; Honscha KU; Jakob J; Lamp J; Schweizer S; Reischauer A; Gottschalk J; Hahn A; Ebert M; Rothemund S; Blaschzik S; Einspanier A
Reprod Domest Anim; 2009 Jul; 44 Suppl 2():224-9. PubMed ID: 19754574
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
[TBL] [Abstract][Full Text] [Related]
6. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
8. Quantification of VEGF-C expression in canine mammary tumours.
Qiu C; Lin DD; Wang HH; Qiao CH; Wang J; Zhang T
Aust Vet J; 2008 Jul; 86(7):279-82. PubMed ID: 18616481
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues.
Gama A; Gärtner F; Alves A; Schmitt F
Res Vet Sci; 2009 Dec; 87(3):432-7. PubMed ID: 19464036
[TBL] [Abstract][Full Text] [Related]
10. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
[TBL] [Abstract][Full Text] [Related]
11. The role of CD44 adhesion factor in canine mammary carcinomas.
Madrazo J; García-Fernández RA; García-Iglesias MJ; Durán AJ; Espinosa J; Pérez-Martínez C
Vet J; 2009 Jun; 180(3):371-6. PubMed ID: 18299241
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of progesterone and cellular proliferation in canine mammary tumours.
Thuróczy J; Reisvaag GJ; Perge E; Tibold A; Szilágyi J; Balogh L
J Comp Pathol; 2007; 137(2-3):122-9. PubMed ID: 17645888
[TBL] [Abstract][Full Text] [Related]
13. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence.
Sorenmo KU; Kristiansen VM; Cofone MA; Shofer FS; Breen AM; Langeland M; Mongil CM; Grondahl AM; Teige J; Goldschmidt MH
Vet Comp Oncol; 2009 Sep; 7(3):162-72. PubMed ID: 19691645
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
[TBL] [Abstract][Full Text] [Related]
15. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
[TBL] [Abstract][Full Text] [Related]
16. Loss of p27 expression in canine mammary tumors and their metastases.
Klopfleisch R; Schütze M; Gruber AD
Res Vet Sci; 2010 Apr; 88(2):300-3. PubMed ID: 19748645
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables.
Matos AJ; Lopes C; Carvalheira J; Santos M; Rutteman GR; Gärtner F
J Comp Pathol; 2006; 134(2-3):182-9. PubMed ID: 16545841
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptors in canine mammary gland tumours.
Sobczak-Filipiak M; Malicka E
Pol J Vet Sci; 2002; 5(1):1-5. PubMed ID: 11944580
[TBL] [Abstract][Full Text] [Related]
20. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene.
Hsu WL; Huang HM; Liao JW; Wong ML; Chang SC
Vet J; 2009 Apr; 180(1):116-23. PubMed ID: 18061495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
